PONTE
VEDRA, Fla., May 9, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD)
a biopharmaceutical company focused on developing tecarfarin, a
late-stage novel cardiorenal therapy with orphan drug and Fast
Track designations, announced today that Quang Pham, CEO, will be participating in a
Company Webcast and Panel Presentation at the Lytham Partners
Spring 2023 Investor Conference on Thursday,
May 18, 2023. Management will also be conducting one-on-one
meetings with investors.
Company Webcast
The Company's webcast presentation
will be available for viewing at 9:00 am ET on Thursday, May 18, 2023, on the Company's website
at https://www.cadrenal.com/investors/ or
https://wsw.com/webcast/lytham8/cad/1827000. The webcast will also
be archived and available for replay.
Panel Presentation
Additionally, Mr. Pham will be
participating in a panel titled, "Phase 3 Drugs to Watch." This
panel, also to be conducted virtually, will be held on Thursday, May 18, 2023, at 2:00 pm ET. To access the panel, please visit:
https://wsw.com/webcast/lytham8/panel3/2272725.
1x1 Meetings
Management will be participating in
virtual one-on-one meetings throughout the event. To arrange a
meeting with management, please contact Lytham Partners at
1x1@lythampartners.com or register at
https://www.lythampartners.com/spring2023invreg/.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is focused on developing tecarfarin, a late-stage
novel cardiorenal therapy with orphan drug and Fast Track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end-stage renal disease,
or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to
target a different pathway than the most commonly prescribed drugs
used in the treatment of thrombosis and AFib. Tecarfarin has been
evaluated in eleven (11) human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials,
tecarfarin has generally been well-tolerated in both healthy adult
subjects and patients with chronic kidney disease (CKD). For more
information, please visit: www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-lytham-partners-spring-2023-investor-conference-301819998.html
SOURCE Cadrenal Therapeutics, Inc.